Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 6410249
Odorant receptors
expired -
US 6410320
Method and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules
expired -
US 6410721
Polynucleotide decoys that inhibit MHC-II expression and uses thereof
expired -
US 6406693
Cancer treatment methods using antibodies to aminophospholipids
expired -
US 6406702
Multivalent in ovo avian vaccine
expired -
US 6405069
Time-resolved optoacoustic method and system for noninvasive monitoring of glucose
expired -
US 6403672
Preparation and use of photopolymerized microparticles
expired -
US 6399633
Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
expired -
US 6399580
Methods and compositions for stimulating tissue growth and epithelial moisturization
expired -
US 6399362
Electrospraying apparatus and method for introducing material into cells
expired -
US 6399368
Secretion of T cell receptor fragments from recombinant Escherichia coli cells
expired -
US 6399762
Methods and compositions for diagnosing and treating chromosome -18p related disorders
expired -
US 6395253
Microspheres containing condensed polyanionic bioactive agents and methods for their production
expired -
US 6395712
Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy
expired -
US 6395709
Methods and compositions for stimulating tissue growth and epithelial moisturization
expired -
US 6395882
Selectin ligands
expired -
US 6395510
Vertebrate apoptosis gene: compositions and methods
expired -
US 6391049
Solid biodegradable device for use in tissue repair
expired -
US 6391888
Topical anesthetics useful for treating cancer
expired -
US 6391848
Soybean protein nutraceuticals
expired -
US 6391574
AFC1 and RCE1: isoprenylated CAAX processing enzymes
expired -
US 6391554
Detecting cancerous conditions by assaying for telomerase activity
expired -
US 6387700
Cationic peptides, Cys-Trp-(Lys)n, for gene delivery
expired -
US 6383760
Transcriptionally regulated G protein-coupled receptor
expired -
US 6384191
Receptors for fibroblast growth factors
expired -
US 6384015
Selective lysis of malaria infected erythrocytes
expired -
US 6383764
Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP)
expired -
US 6379955
Optical fiberless sensors
expired -
US 6380371
Endoglycan: a novel protein having selectin ligand and chemokine presentation activity
expired -
US 6380403
Illudin analogs useful as antitumor agents
expired -
US 6379664
Composition and method for the prevention and treatment of oxidative damage in ocular tissues
expired -
US 6375925
Methods and reagents for non-invasive imaging of atherosclerotic plaque
expired -
US 6376467
Use of inhibitors of protein kinase C epsilon to treat pain
expired -
US 6376196
Recombinant neospora antigens and their uses
expired -
US 6375930
Membrane incorporation of texaphyrins
expired -
US 6372250
Non-invasive gene targeting to the brain
expired -
US 6371992
Acellular matrix grafts: preparation and use
expired -
US 6372217
Methods for the treatment of CD7+ viral infection with TXU-7-PAP
expired -
US 6372455
Recombinant vaccinia viral vectors
expired -
US 6372957
Transgenic mouse comprising a MEF2 binding site operatively linked to an indicator gene and methods of use
expired -
US 6369101
Therapeutic method to treat herpes virus infection
expired -
US 6368593
Enhanced immunogenic cell populations prepared using H2 receptor antagonists
expired -
US 6369095
Indole-3-carbinol (13C) derivatives and methods
expired -
US 6368596
Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
expired -
US 6369097
Treatment and prevention of hepatic disorders
expired -
US 6365365
Method of determining whether an agent modulates glycosyl sulfotransferase-3
expired -
US 6365630
Compositions and methods for inhibiting photoaging of skin
expired -
US 6365797
Mice models of human prostate cancer progression
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory